Zola-cel cell therapy for autoimmune blood disorders
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests Zola-cel, a new cell therapy treatment, in people with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA)—conditions where the body's immune system attacks blood cells. The therapy may help people whose blood counts haven't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with chronic ITP (low platelets) or AIHA (low red blood cells) without other systemic autoimmune diseases
- Failed or couldn't tolerate at least 2 different types of prior treatments (specific combinations depend on your diagnosis)
- Platelet count below 30 (or below 50 if on TPO-RA medication) for ITP, or hemoglobin below 10 for AIHA
- No active hepatitis C, HIV, or recent cancer history (must be cancer-free for ≥2 years)
- Adequate liver, kidney, and blood cell counts (within protocol limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.